ライフサイエンスコーパス: final diagnosis

1 ts (celiac disease, no celiac disease, or no final diagnosis).

2 rcolepsy were compared within group by their final diagnosis.

3 y were calculated by comparing findings with final diagnosis.

4 vity, an average of 75.8 months prior to the final diagnosis.

5 m shown in the imaging studies confirmed our final diagnosis.

6 e diagnosis or 2-y follow-up established the final diagnosis.

7 eriappendiceal inflammation was used for the final diagnosis.

8 Histology or clinical follow-up was used for final diagnosis.

9 and a more accurate physician impression of final diagnosis.

10 e the main route of clinical work-up towards final diagnosis.

11 n between clinical and CT parameters and the final diagnosis.

12 bability of the patient having CHF and their final diagnosis.

13 position, problems occurred in determining a final diagnosis.

14 ogic subtype, tissue biopsy is necessary for final diagnosis.

15 for the distribution of changes, and likely final diagnosis.

16 consensus readings were correlated with the final diagnosis.

17 rns were reviewed and were compared with the final diagnosis.

18 ne at the acute stage, and their primary and final diagnosis.

19 All images led to a clear final diagnosis.

20 the proposed risk factors, and reported the final diagnosis.

21 plays an important role in establishing the final diagnosis.

22 simplified algorithmic approach to reach the final diagnosis.

23 ar-perfect agreement (kappa = 0.86) with the final diagnosis.

24 ing additional examinations to determine the final diagnosis.

25 irect further investigation that may yield a final diagnosis.

26 d identify clinical features associated with final diagnosis.

27 ce between groups in the rate of alternative final diagnosis.

28 ing the diagnostic efficiency and making the final diagnosis.

29 2019 and April 2020 and (b) availability of final diagnosis.

30 ce were evaluated for two readers blinded to final diagnosis.

31 nd not to have celiac disease, and 24 had no final diagnosis.

32 D) and yet were found to have an alternative final diagnosis.

33 s, biochemical workup, any intervention, and final diagnosis.

34 y, an additional CT test enables stating the final diagnosis.

35 hecal and systemic immunity, irrespective of final diagnosis.

36 es ECPW examination proved conclusive to the final diagnosis.

37 pectively reviewed by a grader masked to the final diagnosis.

38 erienced technicians masked to the patients' final diagnosis.

39 ed by comparing EBUS-TBNA diagnosis with the final diagnosis.

40 outcomes, including VA, recurrence risk, and final diagnosis 2 years after enrollment.

41 alysis was the sole predictor of obtaining a final diagnosis (2.3 [1.4-3.8]; p = 0.02).

42 were 6 patients who did not have STEMI as a final diagnosis; 5 had takotsubo cardiomyopathy and 1 ha

43 Among 496 participants with a final diagnosis, 73 individuals (14.7%) were classified

44 ncluded time spent per case (in seconds) and final diagnosis accuracy.

45 s with serial changes was compared against a final diagnosis adjudicated by 2 independent cardiologis

46 An expert panel assigned final diagnosis after 3 months.

47 y computed tomography angiography versus the final diagnosis after invasive endotyping.

48 Uncertainty about the final diagnosis after LCBB is associated with substantia

49 This approach ensures that the final diagnosis aligns with the physician's understandin

50 ysis were used to identify predictors of the final diagnosis among several variables.

51 diagnosis in 65% of cases; but agreement on final diagnosis among the four pathologists was complete

52 gnostic stability, while a high FGRS for the final diagnosis and a low FGRS for the incident diagnosi

53 en than in men in terms of time to reach the final diagnosis and downstream testing.

54 h the role of radiological procedures in the final diagnosis and further treatment of such cases.

55 Correlation between the final diagnosis and imaging or clinicobiochemical parame

56 clinically infected or noninfected based on final diagnosis and management.

57 similar characteristics, independent of the final diagnosis and prognosis.

58 ignificant association was found between the final diagnosis and the SUV(max), prostate-specific anti

59 of other confounders including age, gender, final diagnosis and thrombolysis treatment (odds ratio [

60 nalyzed for accuracy via comparison with the final diagnosis and top 3 differential diagnosis provide

61 cent agreement across subspecialties for the final diagnosis and top 3 differential diagnosis was 59%

62 requency of disease occurrences, and time to final diagnosis and treatment.

63 er small bowel transplantation, the work-up, final diagnosis, and evolution.

64 the poorest), NHIF usage, coping strategies, final diagnosis, and health system level at which they w

65 Demographic information, final diagnosis, and NMFP-OCT findings were collected.

66 ry CT signs of mediastinitis and a different final diagnosis, and those with neither primary CT findi

67 Primary outcomes were final diagnosis, antibiotic use, and need for hospitaliz

68 differential diagnosis, neuropathology, and final diagnosis are discussed here.

69 logic decline, neuropathologic findings, and final diagnosis are discussed.

70 erential diagnosis, pathologic findings, and final diagnosis are discussed.

71 Physicians indicated the correct final diagnosis as most likely among their viable diagno

72 With final diagnosis as the reference standard, we tested the

73 With final diagnosis as the reference, 2564 of the 4824 patie

74 both sample types by local pathologists and final diagnosis at a second MDA (MDA2), anonymized TBLC

75 on on specimen radiographs was compared with final diagnosis at surgical excision.

76 ther diagnostic algorithm or, in many cases, final diagnosis based exclusively on an MRI examination.

77 nostics and, in many cases, establishing the final diagnosis based on MR examination.

78 orrectly were calculated in reference to the final diagnosis, based on compound results of clinical,

79 e both independent variables associated with final diagnosis, but lesion size was not an independent

80 rtment and using central adjudication of the final diagnosis by 2 independent cardiologists, the diag

81 Final diagnosis by allergists was considered the referen

82 The proportion of patients with a final diagnosis by EBUS-TBNA in whom subtype was classif

83 with findings from MR imaging and CT and the final diagnosis by means of logistic regression.

84 The reference standard was the final diagnosis by the Endocarditis Team or expert clini

85 olled patients against a reference standard (final diagnosis), centrally adjudicated by 2 independent

86 over the same period who had an alternative final diagnosis (CJD mimics).

87 Final diagnosis classified patients as "hypersensitive,"

88 llent concordance with the blinded consensus final diagnosis (Cohen k = 0.80).

89 ing provider details, consultation question, final diagnosis, complexity of consultation, time of con

90 framework to assist the radiologists with a final diagnosis decision.

91 ths to 5 years following biopsy to determine final diagnosis, delayed complications, and influence of

92 emographics, prior care, referral diagnosis, final diagnosis, diagnostic testing, treatment, patient

93 c information has the greatest impact on the final diagnosis, especially when the initial clinical/ra

94 The final diagnosis established after laparotomy and rereadi

95 Final diagnosis for 15 patients (78.9%) was FEVR, and fi

96 gnosis for 15 patients (78.9%) was FEVR, and final diagnosis for 4 patients (21.1%) was TBD.

97 The second most common final diagnosis for each of these MD, schizophrenia, BD,

98 ists and six radiology residents (blinded to final diagnosis) for the presence of PE using three type

99 ologic and microbiologic confirmation of the final diagnosis, formed the basis of this investigation.

100 eatment including radiotherapy and in whom a final diagnosis had been determined by histologic examin

101 16 (10%) of 161 patients with a final diagnosis had somatic mutations.

102 In 53 patients (80%) with lymphoma as a final diagnosis, histologic subclassification was suffic

103 Final diagnosis: hypersensitivity pneumonitis in 47.3% (

104 ligible patients, NSTEMI was the adjudicated final diagnosis in 1051 (18.6%) patients.

105 Appendicitis was the final diagnosis in 118 cases.

106 AMI was the adjudicated final diagnosis in 127 patients (15%); cardiac noncorona

107 AMI was the final diagnosis in 156 patients (7.9%).

108 MI was the adjudicated final diagnosis in 178 of 1,261 patients (14%).

109 MI was the adjudicated final diagnosis in 214 (19%) of 1,102 patients.

110 Acute myocardial infarction was the final diagnosis in 36% of all patients with renal dysfun

111 te hepatitis C virus (HCV) infection was the final diagnosis in 4 of 9 unlikely cases.

112 atients, acute myocardial infarction was the final diagnosis in 451 (16%) patients.

113 The final diagnosis in all patients was adjudicated on the b

114 ular subtyping data in 99 cases, amended the final diagnosis in five cases, and making potentially si

115 The hierarchical reporting of final diagnosis in NLST may have been associated with an

116 oximately 10 times more likely than a benign final diagnosis in participants with PET results rated d

117 malignancy, there was a significant delay to final diagnosis in the CT group compared with the (18)F-

118 Cerebrovascular disease was a more common final diagnosis in the teleradiology cases (13 of 135 [9

119 , electron microscopy was needed to make the final diagnosis; in two of these cases, the preliminary

120 % at US; 82 of 109, 75% at MR) than when the final diagnosis included other anomalies as well (14 of

121 The final diagnosis is always based on histopathological exa

122 Final diagnosis is established with immunohistochemical

123 to an appropriate differential diagnosis and final diagnosis is highlighted in our case report.

124 Final diagnosis is made on full-thickness biopsy.

125 The final diagnosis is more quickly achieved in patients whe

126 based on SD OCT alone was compared with the final diagnosis made using ICGA and fluorescein angiogra

127 ity of MCAS, and thus establishing the exact final diagnosis, may greatly help in the management and

128 re low-grade renal cell carcinomas (RCCs) at final diagnosis, no patients died of RCC, including thos

129 TI-RADS categorisations were compared to the final diagnosis obtained by cytopathological/histopathol

130 d by CT enterography was correlated with the final diagnosis obtained from histopathology.

131 These abnormalities were compared with the final diagnosis obtained from the medical records, inclu

132 ently reviewed case summaries and assigned a final diagnosis of "IE" or "not IE," which served as the

133 nificant incident findings were defined as a final diagnosis of a negative screen result with signifi

134 ery with histologic confirmation established final diagnosis of abnormal middle ear cleft soft tissue

135 sitivity of BMIPP by 3 blinded readers for a final diagnosis of ACS and intermediate likelihood of AC

136 Functional outcomes of patients with final diagnosis of acute cerebral ischemia who were elig

137 ted stroke in 14 patients, all of whom had a final diagnosis of acute stroke.

138 he children, including 79 (92%) of 86 with a final diagnosis of AHO.

139 a deep learning algorithm that predicts the final diagnosis of Alzheimer disease (AD), mild cognitiv

140 The final diagnosis of AMI was independently adjudicated usi

141 women (14.5%) and 345 men (18.6%) received a final diagnosis of AMI.

142 A final diagnosis of AP, established by expert review of h

143 state of New South Wales, Australia, with a final diagnosis of arterial ischemic stroke (AIS) in pat

144 Two endocrinologists independently made the final diagnosis of AVP deficiency or primary polydipsia

145 greater was significantly correlated with a final diagnosis of BD (p<0.05; area under the curve (AUC

146 A final diagnosis of BMI was considered if the BMB was pos

147 A final diagnosis of bone metastases was made for 211 of 2

148 Among 113 (69.8%) patients with a final diagnosis of botulism, those treated early (<=2 da

149 Two (1.2%) of 161 lesions with a final diagnosis of carcinoma were benign at LCNB but mal

150 s between expert fetal cardiac diagnosis and final diagnosis of CHD and their impact on neonatal and

151 Of the 452 patients with a final diagnosis of CHF, 165 (36.5%) had preserved left v

152 The final diagnosis of CIED infection by the endocarditis ex

153 A final diagnosis of CNS, complicated with peritonitis tra

154 an algorithm to guide clinicians towards the final diagnosis of conditions characterised by the co-oc

155 2-dimensional echocardiography and who had a final diagnosis of CP (n=28), RCM (n=30), or no structur

156 A final diagnosis of Crohn's disease, type of reservoir (J

157 sensitivity and specificity calculations was final diagnosis of CS injury at the time of discharge.

158 Final diagnosis of CS was established using Japanese Min

159 participants) were included, 14 (35%) with a final diagnosis of CS.

160 l and radiological database of patients with final diagnosis of CVT was analyzed.

161 inical characteristics of individuals with a final diagnosis of dementia with Lewy Bodies (DLB), Park

162 We compared the manometry metrics and the final diagnosis of EMDs between patients taking still wa

163 Patients with a final diagnosis of encephalitis were more frequently fem

164 lacrimal gland involvement, of whom 7 had a final diagnosis of GPA.

165 ar CT and MR scan reformations helped to the final diagnosis of hemangioma, showing its origin from t

166 , with lower to higher stroke severity) with final diagnosis of ICH were included.

167 dence at 90 days for patients who received a final diagnosis of ICH.

168 nd 3 of colorectal cancer in patients with a final diagnosis of IE.

169 A final diagnosis of infection was based on microbiologic

170 A final diagnosis of infection was confirmed in 31 patient

171 The final diagnosis of infection was established by the IE S

172 A final diagnosis of insulin-secreting tumor was reached i

173 A final diagnosis of insulinoma was determined by patholog

174 fferent protocols among patients receiving a final diagnosis of intracerebral hemorrhage (ICH) is unk

175 CFR, 34.6% had abnormal IMR, and 48.1% had a final diagnosis of invasively determined CMD.

176 ) at 90 days in the target population with a final diagnosis of ischemic or hemorrhagic stroke.

177 dy that included consecutive patients with a final diagnosis of ischemic stroke who received either p

178 Significantly fewer individuals received a final diagnosis of LTBI in the post-QFT-GIT period (397/

179 8%) of those receiving QFT-GIT testing had a final diagnosis of LTBI, while 167/168 (99%) of those wi

180 men radiographs were more likely to enable a final diagnosis of malignancy than were cores without ca

181 diagnosis: those with primary CT signs and a final diagnosis of mediastinitis, those with primary CT

182 those with neither primary CT findings nor a final diagnosis of mediastinitis.

183 andomly assigned to a treatment group with a final diagnosis of mesothelioma).

184 antibodies to clustered AChRs, and 42 had a final diagnosis of MG.

185 87 patients, 1106 (18.8%) had an adjudicated final diagnosis of MI; of these, 860 patients (77.8%) ha

186 Clinical features associated with a final diagnosis of MOGAD in those with suspected MS incl

187 r narcolepsy) were compared within groups by final diagnosis of narcolepsy/hypocretin deficiency.

188 Final diagnosis of NET recurrence was determined in 29 p

189 ral segments, AQP4-IgG seropositivity, and a final diagnosis of NMO or NMOSD.

190 All patients with a final diagnosis of non-prion disease (71 CSF and 67 OM s

191 ters were evaluated in 1,178 patients with a final diagnosis of NSTEMI presenting <24 h after symptom

192 The final diagnosis of positive PET lesions was based on his

193 positive in the remaining 9 patients with a final diagnosis of possible IMD at the end of the study.

194 In 15 of 24 patients with a final diagnosis of possible IMD, CTPA findings were nega

195 From 355 cases with final diagnosis of PTB, 263 (71.8%) had definite diagnos

196 tly higher than the group of patients with a final diagnosis of pulmonary disease (n = 85) whose BNP

197 Correlations between RT-QuIC results and the final diagnosis of recruited patients.

198 g noncaseating granulomas in patients with a final diagnosis of sarcoidosis.

199 Twenty-nine patients had a final diagnosis of SBO, and 71 patients did not.

200 G-appropriate patients, only 247 (82%) had a final diagnosis of STEMI.

201 with early symptom resolution, defined as a final diagnosis of stroke with resolution of presenting

202 tissue-defined averted stroke, defined as a final diagnosis of stroke with resolution of presenting

203 d for analysis, including 55 patients with a final diagnosis of stroke.

204 yers are fused using another BNN to make the final diagnosis of the B-scan.

205 athologic information that substantiated the final diagnosis of the cause of death.

206 gnificant amount of information facilitating final diagnosis of the cause of IDDS therapy failure.

207 llow-up record was not yet available and the final diagnosis of the detected lesion has not yet been

208 There was a definitive final diagnosis of the nature of the mass lesions in 21

209 race, premorbid hypertension, diabetes, and final diagnosis of the qualifying event (stroke vs TIA).

210 The final diagnosis of the qualifying event was cerebral isc

211 In most cases, the final diagnosis of the type of colitis is based on clini

212 tire cohort and for only the patients with a final diagnosis of vasculitis.

213 and 29% to 75% for only the patients with a final diagnosis of vasculitis.

214 ompletion of the trial, without knowledge of final diagnosis or outcome, the investigators classified

215 All data about final diagnosis, organ involvement assessments, and outc

216 Ophthalmology notes were reviewed for final diagnosis, patient disposition, and procedural int

217 In 9 patients (25%) aged 2-16 years the final diagnosis qualified the patients to the group of o

218 Specific histological diagnosis and final diagnosis rates were 62.1% and 75.9%, respectively

219 correlation between the CT diagnosis and the final diagnosis regarding the level and type of obstruct

220 charged from the hospital during 1993 with a final diagnosis-related groups code of 483.

221 test result and 14 had no information as to final diagnosis, resulting in 5461 included in the final

222 LBs were more frequently concordant with the final diagnosis retained at MDA.

223 Compared with the final diagnosis, single-plane digital pulmonary angiogra

224 However, final diagnosis still remains surgical even though imagi

225 pre-operative evaluation of cystic thymoma, final diagnosis still remains surgical.

226 ir diagnostic procedures repeated and have a final diagnosis that differs from that of the referring

227 Compared with the final diagnosis, the CMR diagnosis was accurate in 98.4%

228 211 adnexal masses were correlated with the final diagnosis; the most discriminating features for ma

229 Blinded to final diagnosis, three radiologists independently applie

230 ng three groups: patients who did not have a final diagnosis (uncertain group), patients who knew the

231 Two cardiologists centrally adjudicated the final diagnosis using all clinical data including cardia

232 dent cardiologists centrally adjudicated the final diagnosis using all clinical data, including seria

233 gery, or more aggressive surgery, than their final diagnosis warranted.

234 he overall accuracy of GPT-3.5 and GPT-4 for final diagnosis was 53.7% (182 of 339) and 66.1% (224 of

235 The final diagnosis was a type of FDEIA caused by 39 kDa and

236 rological evaluation excluded paralysis, our final diagnosis was ACC type VII.

237 The final diagnosis was adenoma in 127 masses and non-adenom

238 The final diagnosis was adjudicated by 2 independent cardiol

239 The final diagnosis was adjudicated in patients presenting w

240 Final diagnosis was allergic fungal rhinosinusitis (AFRS

241 Final diagnosis was AMI in 340 patients (17%).

242 A malignant final diagnosis was approximately 10 times more likely t

243 Correct final diagnosis was attained in 97 (88%) patients.

244 In 82 patients in whom a final diagnosis was available, the sensitivity, specific

245 Final diagnosis was based on a combination of EUS-FNA, s

246 lectrocardiograms, and troponin, whereas the final diagnosis was based on all available data (includi

247 The final diagnosis was based on chart review at a minimum 1

248 Final diagnosis was based on clinical follow-up, cytolog

249 The final diagnosis was based on histopathological examinati

250 Final diagnosis was based on surgery or histopathology.

251 marily medical management as "probable IAC," final diagnosis was CCa (n = 3) and IAC (n = 9), while 1

252 The final diagnosis was centrally adjudicated by 2 independe

253 The final diagnosis was centrally adjudicated by 2 independe

254 Interventions: The final diagnosis was centrally adjudicated by 2 independe

255 The final diagnosis was centrally adjudicated by 2 independe

256 The final diagnosis was CHF in 722 (47%) participants.

257 t died 22 years after symptom onset, and the final diagnosis was confirmed at autopsy.

258 The final diagnosis was confirmed by a biopsy.

259 typical features of PD were included if the final diagnosis was confirmed by a suitable criterion st

260 The final diagnosis was confirmed with histopathologic exami

261 The final diagnosis was defined according to the clinical an

262 A final diagnosis was determined after follow-up using all

263 When the final diagnosis was determined from pathology reports, c

264 Final diagnosis was determined with histopathologic veri

265 The final diagnosis was dyspnea due to congestive heart fail

266 Final diagnosis was established after extended diagnosti

267 Final diagnosis was established at surgery (n = 29) and

268 The final diagnosis was established based on selective angio

269 Final diagnosis was established with pathologic analysis

270 The final diagnosis was established with surgical resection

271 Final diagnosis was established with surgical, pathologi

272 The most common final diagnosis was idiopathic (n = 46, 43.0%), followed

273 with confidence to have a small VSD, but the final diagnosis was intermediate VSD in 4, innocent murm

274 Final diagnosis was ischemia (78%), hemorrhage (14%), or

275 Consensus was more likely when the final diagnosis was isolated VM (83 of 104, 80% at US; 8

276 to assess growth in 13 patients for whom the final diagnosis was known and whose initial nodule diame

277 The final diagnosis was made by histopathology in 22 patient

278 A final diagnosis was made by surgical exploration or clin

279 lectron microscopy was then performed, and a final diagnosis was made.

280 elated with histopathological findings and a final diagnosis was made.

281 s specialists for an average of 2.2 y before final diagnosis was made.

282 The final diagnosis was MS in 57%, idiopathic in 29%, MOG-Ig

283 The final diagnosis was obtained by pathologic (n = 56) or c

284 The final diagnosis was obtained by pathology (n = 44) or cl

285 The final diagnosis was pancreatic malignancy (n = 60), acut

286 g tests for PE were obtained and whether the final diagnosis was PE.

287 Final diagnosis was reached by consensus (198 US, 198 MR

288 These findings were confirmed when the final diagnosis was readjudicated with the use of hs-cTn

289 ticipated in the imaging experiment prior to final diagnosis was tracked and diagnoses confirmed at a

290 The final diagnosis was verified only in 83 patients.

291 Clinical course, visual outcome, and final diagnosis were analyzed for 75 patients (81 eyes)

292 bution of PET and morphologic imaging to the final diagnosis were assessed.

293 Cells indicating the final diagnosis were contained in 249 (75%) of 334 speci

294 Patients who had a different final diagnosis were excluded.

295 GRS profiles for incident cases confirmed at final diagnosis were more homogenous than genetic profil

296 nces, cardiac CT led in both sexes to a fast final diagnosis when compared with functional testing, a

297 ity), an average of 75.8 months prior to the final diagnosis, which in ROC space outperformed reader

298 al information that they can use to make the final diagnosis with greater confidence and precision.

299 Cytopathology Society and compared to their final diagnosis with histopathology and/or clinical foll

300 ty and the specificity of MR imaging for the final diagnosis with the potential for a substantial dos